John Wat, DO
Family Medicine · Lowville, NYNPI 1841223096
Payments from drug & device makers
Across 114 payments — averaging $28.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$720
- Novo Nordisk$551
- Lilly USA, LLC$399
- Exact Sciences$229
- GSK$182
- Johnson & Johnson$168
- plus $992 from 14 others
What the payments were for
- Food & beverage$3,240100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $720 |
| Novo Nordisk | 19 | $551 |
| Lilly USA, LLC | 15 | $399 |
| Exact Sciences | 7 | $229 |
| GSK | 8 | $182 |
| Johnson & Johnson | 3 | $168 |
| Amgen | 9 | $163 |
| Merck | 6 | $158 |
| Novartis | 7 | $131 |
| Boehringer Ingelheim | 6 | $112 |
| Boston Scientific | 2 | $108 |
| Hydrofera LLC | 1 | $103 |
| Pfizer | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $31 |
| Dexcom, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| AbbVie | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$250
- BREZTRI$125
- AIRSUPRA$125
- The Cologuard Plus Collection Kit$115
- HYDROFERA BLUE$103
- TRULICITY$100
How this compares
$3,240 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $75,548 |
| EliquisApixaban | 52 | $59,954 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $51,503 |
| JardianceEmpagliflozin | 41 | $44,416 |
| TrulicityDulaglutide | 38 | $44,051 |
| XareltoRivaroxaban | 19 | $29,727 |
| JanuviaSitagliptin Phosphate | 13 | $15,575 |
| FarxigaDapagliflozin Propanediol | 17 | $12,523 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $9,251 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,522 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $3,766 |
| Atorvastatin Calcium | 267 | $3,297 |
| Famotidine | 68 | $2,903 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $2,739 |
| Omeprazole | 156 | $2,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $551 | $75,54883 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $182 | $66,277102 claims |
| PfizerEliquis | $48 | $59,95452 claims |
| Boehringer IngelheimJardiance | $112 | $44,41641 claims |
| Lilly USA, LLCTrulicity | $399 | $44,05138 claims |
| Johnson & JohnsonXarelto | $168 | $29,72719 claims |
| MerckJanuvia | $158 | $15,57513 claims |
| AstraZenecaFarxiga | $720 | $12,52317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Lowville
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.